摘要
目的总结注射用头孢哌酮钠舒巴坦钠致大疱性表皮松解性药疹的治疗体会。方法选择本院于2015年1月28日收治的1例"重症肺炎、呼吸衰竭"患者作为研究对象,分析研究对象抗菌药物致大疱性表皮松解性药疹的发展过程和治疗经过。结果 2015年2月7日与2015年2与27日实验室检查项目比较:在白细胞和中性细胞百分比方面,P<0.05,差异具有统计学意义,其他项目,P>0.05,差异不具有统计学意义。结论注射用头孢哌酮钠舒巴坦钠可导致患者出现大疱性表皮松解性药疹,提示临床医师在使用此类药物时详细询问患者的过敏史,并在用药初期高度密切监测不良反应的发生情况。
Objective To summarize the Cefoperazone sodium and cefoperazone sodium for injection to epidermolysis bullosa experience for the treatment of drug eruption. Methods Selected 1 cases with severe pneumonia, respiratory failure on January 28, 2015 in our hospital as the research object, analysis the research object of antimicrobial drugs cause epidermolysis bullosa drug development process. Results On February 7th with 2 compared with 27 laboratory projects, in terms of white blood cells and neutral cell percentage, P〈0.05, had difference statistically signiifcance. Other projects, P〉0.05, had no difference statistically significance. Conclusion Cefoperazone sodium and cefoperazone sodium for injection can lead to epidermolysis bullosa patients drug eruption, prompt clinical physicians in the use of these drugs when ask for details of the patient＆#39;s history of allergies, and at the beginning of the drug highly close monitoring of the occurrence of adverse reactions.
出处
《中国继续医学教育》
2015年第16期121-122,共2页
China Continuing Medical Education
关键词
注射用头孢哌酮钠舒巴坦钠
大疱性表皮松解性药疹
莫西沙星
Cefoperazone sodium and cefoperazone sodium for injection
Epidermolysis bullosa drug eruption
Moxilfoxacin
